A Randomized, Controlled Trial Evaluating Perioperative Risk-Stratification and Risk-Based, Protocol-Driven Management After Elective Major Cancer Surgery
Nestor F. Esnaola,Raju Chelluri,Jason Castellanos,Ariella Altman,David Y.T. Chen,Christina Chu,Jeffrey M. Farma,Alan Haber,Fathima Sheriff,Christine Huang,Alexander Kutikov,Sameer Patel,Kenneth Patrick,Sanjay Reddy,Stephen Rubin,Rosalia Viterbo,John A Ridge,Martin Edelman,Eric Ross,Marc Smaldone,Robert G. Uzzo
DOI: https://doi.org/10.1097/sla.0000000000006446
IF: 13.787
2024-07-24
Annals of Surgery
Abstract:Objective: We evaluated the efficacy of risk-based, protocol-driven management versus (vs) usual management after elective major cancer surgery to reduce 30-day rates of postoperative death or serious complications (DSC) . Summary Background Data: Major cancer surgery is associated with significant perioperative risks which result in worse long-term outcomes. Methods: Adults scheduled for elective major cancer surgery were stratified/randomized to risk-based escalating levels of care, monitoring, and co-management vs usual management. The primary study outcome was 30-day rate of DSC. Additional outcomes included complications, adverse events, health care utilization, health-related quality of life (HRQOL), and disease-free and overall survival (DFS and OS). Results: Between August 2014 and June 2020, 1529 patients were enrolled and randomly allocated to the study arms; 738 patients in the Intervention Arm and 732 patients in the Control Arm were eligible for analysis. 30-day rate of DSC with the intervention was 15.0% (95% CI, 12.5-17.6%) vs 14.1%, (95% CI, 11.6-16.6%) with usual management ( P =0.65). There were no differences in 30-day rates of complications or adverse events (including return to the operating room); postoperative length of stay; rate of discharge to home; or 30, 60, or 90-day HRQOL or rates of hospital readmission or receipt of anti-neoplastic therapy between the study arms. At median follow-up of 48 months, OS ( P =0.57) and DFS ( P =0.91) were similar. Conclusions: Risk-based, protocol-driven management did not reduce 30-day rate of DSC after elective major cancer surgery compared to usual management, nor improve postoperative health care utilization, HRQOL, or cancer outcomes. Trials are needed to identify cost-effective, tailored perioperative strategies to optimize outcomes after major cancer surgery.
surgery